The Effect of Local Application of Tranexamic Acid Versus Placebo on Postoperative Complications in Plastic Surgery.

S

St. Olavs Hospital

Status and phase

Not yet enrolling
Phase 4

Conditions

Surgical Complication

Treatments

Drug: Tranexamic Acid 100 MG/ML
Drug: 0.9%sodium chloride

Study type

Interventional

Funder types

Other

Identifiers

NCT06270407
2023-510381-28-00 (Registry Identifier)
270777
2022-001580-28 (EudraCT Number)

Details and patient eligibility

About

Study objective: This is a study to investigate whether applying the drug tranexamic acid (TXA) onto a surgical wound surface may affect the incidence of surgical complications such as re-bleeding needing intervention, wound complications such as infection, wound rupture or seroma, or if it may increase the risk of blood clots. Eligible patients: Patients undergoing plastic surgical procedures with wounds that would normally receive application of TXA to reduce bleeding after surgery. Study intervention: Participants will receive a single local application of study drug onto their wound surfaces at the end of surgery. Study drug will be identical looking ampoules which contain either TXA or placebo (saline). Neither participants nor study personnel will know the contents of the ampoules.

Full description

Any serious postoperative complication needing intervention, specifically re-bleeding, wound infection, wound rupture, or the occurrence of blood clots for the first 30 days after surgery will be registered through the following interventions: Screening of patient medical records Distribution of an electronic self-report form (eForsk®) to participating patients at postoperative day 30 Follow-up phone call to verify data after day 30. The study is terminated after the final phone call. All study data will be registered in an electronic, pseudonymous web-based registration form (eCRF/Viedoc®). Number of participants: To assess the effect of TXA on the defined surgical complications compared to placebo, 1500 patients are needed in each group. Data monitoring committee: A data monitoring committee consisting of a group of independent scientists will be appointed for this study to monitor the safety and scientific integrity of this human research intervention.

Enrollment

3,000 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients are eligible to be included in the study only if all of the following criteria apply:

  • They are to undergo a surgical procedure within the field of plastic surgery where the procedure involves use of topical TXA at the participating center.
  • They are over 18 years of age and capable of independently providing informed consent
  • They have received adequate oral and written information about the study and signed the informed-consent form

Exclusion criteria

Patients with known allergy to tranexamic acid. Insufficient knowledge of national language or English.

Trial design

Primary purpose

Prevention

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

Quadruple Blind

3,000 participants in 2 patient groups, including a placebo group

Tranexamic acid arm
Active Comparator group
Description:
Anonymous ampoule containing 5 ml of 100 mg/ml Tranexamic Acid. If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using Tranexamic Acid.
Treatment:
Drug: Tranexamic Acid 100 MG/ML
Placebo arm
Placebo Comparator group
Description:
Anonymous ampoule containing 5 ml of 0.9% NaCl. If surgeon wants to apply tranexamic acid onto the wound surface, the study ampoule will be diluted and applied in accordance with the surgeon's practice when using Tranexamic Acid.
Treatment:
Drug: 0.9%sodium chloride

Trial contacts and locations

0

Loading...

Central trial contact

Kjersti Ausen, MD PhD; Olav Spigset, MD PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems